| Effect of Oral Ramosetron for Postoperative Nausea and Vomiting in Surgical Patients using PatientControlled Analgesia. |
|
Hyeon Jeong Lee, Chang Seok Shin, Bong Soo Choi, Ji Young Yoon, Jae Young Kwon, Hae Kyu Kim |
|
Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Busan, Korea. hakykim@pusan.ac.kr |
|
|
|
|
|
| Abstract |
BACKGROUND
This study was designed to evaluate ramosetron oral disintegrating tablet (ODT), a 5-HT3 receptor antagonist, for prophylaxis and treatment of postoperative nausea and vomiting (PONV) in patients undergoing general anesthesia using patient controlled analgesia (PCA).
METHODS
150 adult, ASA physical status I or II, aged 18-65 yr, patients undergoing elective surgery were enrolled (n = 50 in each). Patients were randomly assigned to one of three groups, group C (no prophylactic antiemetics), groups N (ramosetron ODT 30 minutes before the induction), and group Z (intravenous injection of ondansetron 4 mg at the end of surgery followed by continuous infusion of 8 mg added to the PCA solution). A standard general inhalation anesthesia and IV PCA with fentanyl and ketorolac were used. During the 48 hours after recovery, we assessed pain score by: using a visual analogue scale (VAS), a sedation scale, an incidence of PONV, and monitoring consumption of PCA drug, rescue drug consumption, adverse events, and overall satisfaction.
RESULTS
The incidence of nausea and the consumption of rescue drug were significantly decreased in N and Z groups at each time point except 24-48 hours after recovery. There was no significant difference in incidence of vomiting.
Overall satisfaction was superior in N and Z groups compared with C group.
CONCLUSIONS
Preoperative administration of ramosetron ODT was an acceptable and effective way to prevent PONV in patients using PCA. |
| Key Words:
patient controlled analgesia; postoperative emesis; ramosetron |
|
PDF Links
Full text via DOI
Download Citation
